The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index.
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Open accessAbstract
Glioblastoma is known to be one of the most lethal and untreatable human tumors. Surgery and radiotherapy in combination with classical alkylating agents such as temozolomide offer little hope to escape a poor prognosis. For these reasons, enormous efforts are currently devoted to refine in vivo and in vitro models with the specific goal of finding new molecular aberrant pathways, suitable to be targeted by a variety of therapeutic approaches, including novel pharmaceutical formulations and immunotherapy strategies. In this review, we will first discuss current molecular classification based on genomic and transcriptomic criteria. Also, the state of the art in current clinical practice for glioblastoma therapy in the light of the recent molecular classification, together with ongoing phases II and III clinical trials, will be described. Finally, new pharmaceutical formulations such as nanoparticles and viral vectors, together with new strategies entailing the use of monoclonal antibodies, vaccines and immunotherapy agents, such as checkpoint inhibitors, will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The life expectancy of the GBM patients is ~18 months after diagnosis (2).”
From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Despite the current standard of care that combines surgery, radiotherapy and chemotherapy, GBM patients are nonetheless confronted with frequent recurrence, and hence their life expectancy is very short (1, 2, 34).”
From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Glioblastoma multiform (GBM) is the most aggressive form of brain tumors, glioma.”
From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,210
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
The cellular and molecular basis of hyperthermia
Hildebrandt, B. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00179-2 · Cited by 1,714
Glioblastoma: Overview of Disease and Treatment
Davis, M. E. (2016) · Clinical journal of oncology nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,308
Temozolomide resistance in glioblastoma multiforme
Lee, S. Y. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.04.007 · Cited by 1,173
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
Bhat, K., Balasubramaniyan, V., Vaillant, B. D., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L. E., James, J. D., Goodman, L. D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.001 · Cited by 1,139
Weller, M., Butowski, N. A., Tran, D. D., Recht, L. D., Lim, M. K., Hirte, H. W., Ashby, L. S., Mechtler, L. L., Goldlust, S. A., IWAMOTO, F. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,138
Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq
Venteicher, A. S., Tirosh, I., Hebert, C. M., Yizhak, K., Neftel, C., Filbin, M. G., Hovestadt, V., Escalante, L. E., Shaw, M. L., Rodman, C., et al. (2017) · Science · doi:10.1126/science.aai8478 · Cited by 994
Darmanis, S., Sloan, S. A., Croote, D., Mignardi, M., Chernikova, S. B., Samghababi, P., Zhang, Y., Neff, N. F., Kowarsky, M., Caneda, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.030 · Cited by 991
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D. L., Forsyth, P. A., & Bell, J. C. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1750 · Cited by 555
Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Chen, J., McKay, R. M., & Parada, L. F. (2012) · Cell · doi:10.1016/j.cell.2012.03.009 · Cited by 549
Roos, W. P., Batista, L. F. Z., Naumann, S. C., Wick, W., Weller, M., Menck, C. F. M., & Kaina, B. (2006) · Oncogene · doi:10.1038/sj.onc.1209785 · Cited by 513
Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.002 · Cited by 304
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J., D'Hondt, L. A., Strauven, T., Chaskis, C., Veld, P. I. '., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 260
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
Padfield, E., Ellis, H. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00005 · Cited by 257
Oncolytic Virus Therapy for Glioblastoma Multiforme
Wollmann, G., Özduman, K., & van den Pol, A. N. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824671c9 · Cited by 206
Diffuse Infiltrating Oligodendroglioma and Astrocytoma
van den Bent, M. J., Smits, M., Kros, J. M., & Chang, S. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6737 · Cited by 184
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
Xue, S., Hu, M., Iyer, V. R., & Yu, J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0455-6 · Cited by 172
In Vivo Specific Delivery of c-Met siRNA to Glioblastoma Using Cationic Solid Lipid Nanoparticles
Jin, J., Bae, K. H., Yang, H., Lee, S. J., Kim, H., Kim, Y., Joo, K. M., Seo, S. W., Park, T. G., & Nam, D. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200406n · Cited by 149
Integrins and Exosomes, a Dangerous Liaison in Cancer Progression
Paolillo, M., & Schinelli, S. (2017) · Cancers · doi:10.3390/cancers9080095 · Cited by 132
Self-citationNanoparticles: Novel vehicles in treatment of Glioblastoma
Pourgholi, F., Hajivalili, M., Jadidi‐Niaragh, F., Kafil, H. S., & Yousefi, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.014 · Cited by 120
Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells
Gan, H. K., van den Bent, M. J., Lassman, A. B., Reardon, D. A., & Scott, A. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.95 · Cited by 117
Park, K.-J., Kano, H., Iyer, A., Liu, X., Niranjan, A., Flíckinger, J. C., Lieberman, F. S., Lunsford, L. D., & Kondziolka, D. S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0744-9 · Cited by 109
Zhang, F., Huang, X., Zhu, L., Guo, N., Niu, G., Swierczewska, M., Lee, S., Xu, H. T., Wang, A. Y., Mohamedali, K. A., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.032 · Cited by 108
Carlo, D. T. D., Cagnazzo, F., Benedetto, N., Morganti, R., & Perrini, P. (2017) · Neurosurgical Review · doi:10.1007/s10143-017-0928-7 · Cited by 105
Vitucci, M., Hayes, D. N., & Miller, C. R. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606031 · Cited by 101
Xue, S., Hu, M., Li, P., Ma, J., Xie, L., Teng, F., Zhu, Y., Fan, B., Mu, D., & Yu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17922 · Cited by 98
Aghi, M. K., Visted, T., DePinho, R. A., & Chiocca, E. A. (2008) · Oncogene · doi:10.1038/onc.2008.53 · Cited by 94
Ji, N., Weng, D., Liu, C., Gu, Z., Chen, S., Guo, Y., Fan, Z., Wang, X., Chen, J., Zhao, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6737 · Cited by 91
Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment
Belhadj, Z., Zhan, C., Man, Y. M., Wei, X., Xie, C., Yan, Z., & Lu, W. (2017) · Oncotarget · doi:10.18632/oncotarget.17976 · Cited by 91
Integrins in glioblastoma: Still an attractive target?
Paolillo, M., Serra, M., & Schinelli, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.004 · Cited by 90
Self-citationImmunotherapy for the Treatment of Glioblastoma
Thomas, A. A., Ernstoff, M. S., & Fadul, C. E. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182431a73 · Cited by 90
Mitchell, L., Espinoza, F. L., Mendoza, D., Kato, Y., Inagaki, A., Hiraoka, K., Kasahara, N., Gruber, H. E., Jolly, D. J., & Robbins, J. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox037 · Cited by 86
Glioma virus therapies between bench and bedside
Kaufmann, J. K., & Chiocca, E. A. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not310 · Cited by 79
History and current state of immunotherapy in glioma and brain metastasis
McGranahan, T. M., Li, G., & Nagpal, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017693750 · Cited by 73
Kawaguchi, K., Igarashi, K., Li, S., Han, Q., Tan, Y., Kiyuna, T., Miyake, K., Murakami, T., Chmielowski, B., Nelson, S. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20231 · Cited by 72
Wang, X., Huang, X., Yang, Z., Gallego‐Perez, D., Ma, J., Zhao, X., Xie, J., Nakano, I., & Lee, L. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666141031105234 · Cited by 65
Murakami, J., Lee, Y., Kokeguchi, S., Tsujigiwa, H., Asaumi, J., Nagatsuka, H., Fukui, K., Kuroda, M., Tanaka, N., & Matsubara, N. (2007) · Oncology Reports · doi:10.3892/or.17.6.1461 · Cited by 63
Extended field stereotactic radiosurgery for recurrent glioblastoma
Koga, T., Maruyama, K., Tanaka, M., Ino, Y., Saito, N., Nakagawa, K., Shibahara, J., & Todo, T. (2011) · Cancer · doi:10.1002/cncr.27372 · Cited by 62
Effective treatment of neuroendocrine tumors With temozolomide and capecitabine
Fine, R. L., Fogelman, D. R., & Schreibman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4216 · Cited by 60
Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients
Tejada, S., Alonso, M. M., Patiño‐García, A., Fueyo-Margareto, J., Gomez‐Manzano, C., & Díez-Valle, R. (2017) · Neurosurgery · doi:10.1093/neuros/nyx507 · Cited by 55
Clinical outcomes following salvage gamma knife radiosurgery for recurrent glioblastoma
Larson, E. W. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i2.142 · Cited by 49
Owen, D. H., Alexander, A. J., Konda, B., Wei, L., Hemminger, J. A., Schmidt, C. R., Abdel‐Misih, S., Dillhoff, M. E., Sipos, J. A., Kirschner, L. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22001 · Cited by 42
Basic concepts of immunology and neuroimmunology
Sehgal, A., & Berger, M. S. (2000) · Neurosurgical FOCUS · doi:10.3171/foc.2000.9.6.2 · Cited by 38
Rizvi, N. A., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q. M., Goldman, J. W., Juergens, R. A., Borghaei, H., Ready, N., Gerber, D. E., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.08.204 · Cited by 37
Reardon, D. A., Desjardins, A., Schuster, J. M., Tran, D. D., Fink, K., Nabors, B., Li, G., Bota, D. A., Lukas, R. V., Ashby, L. S., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov218.08 · Cited by 30
Saif, M. W., Kotteas, E. A., & Syrigos, K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s72155 · Cited by 29
Alonso, M. M., García-Moure, M., González-Huarriz, M., Marigil, M., Hernández-Alcoceba, R., Buñales, M., Hervás, S., Pérez‐Larraya, J. G., Gomez‐Manzano, C., Fueyo-Margareto, J., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct027 · Cited by 27
Novel Vaccines for Glioblastoma: Clinical Update and Perspective
Winograd, E. K., Ciesielski, M. J., & Fenstermaker, R. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0059 · Cited by 26
Nawaz, Z., Patil, V., Thinagararjan, S., Rao, S. A. M., Hegde, A. S., Arivazhagan, A., Santosh, V., & Somasundaram, K. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12060 · Cited by 25
An Update in the Use of Antibodies to Treat Glioblastoma Multiforme
Hernández‐Pedro, N., Rangel‐López, E., Félix, G. V., Pineda, B., & Sotelo, J. (2013) · Autoimmune Diseases · doi:10.1155/2013/716813 · Cited by 22
Functional network analysis of gene-phenotype connectivity associated with temozolomide
Shi, J. H., Dong, B., Zhou, P., Guan, W., & Peng, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20848 · Cited by 16
Neagu, M. R., & Reardon, D. A. (2015) · Immunotherapy · doi:10.2217/imt.15.39 · Cited by 15
Kotteas, E. A., Syrigos, K., & Saif, M. W. (2016) · Dove Medical Press (Taylor and Francis Group) · Cited by 13
Sarah, C. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.158 · Cited by 5
Cited by
Sorted by citations
Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Ghosh, D., Nandi, S., & Bhattacharjee, S. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0211-8 · Cited by 233
Lux, F., Tran, V. L., Thomas, E., Dufort, S., Rossetti, F., Martini, M., Truillet, C., Doussineau, T., Bort, G., Denat, F., et al. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180365 · Cited by 189
Zhang, P., Qin, X., Liu, L., Li, S., & Dong, L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.562798 · Cited by 169
Therapy for glioblastoma: is it working?
Zanders, E. D., Svensson, F., & Bailey, D. S. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.008 · Cited by 135
Metadata
- Authors
- Paolillo, M., Boselli, C., & Schinelli, S.
- Affiliations
- University of Pavia (IT)
- Corresponding author
- Paolillo, Mayra
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2018-01-16
- Volume
- 8
- Issue
- 1
- Pages
- 15
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC5789346
- OpenAlex
- W2788894351
- Cited by
- 135
- References
- 68
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 10 · 2023: 4 · 2022: 17 · 2021: 24 · 2020: 25 · 2019: 27 · 2018: 12
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- glioblastoma, molecular classification, temozolomide, alkylating agents, combination therapy, clinical trials, nanoparticles, viral vectors, monoclonal antibodies, cancer vaccines, immunotherapy, immune checkpoint inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
